Susan J. Knox
YOU?
Author Swipe
View article: RADx-UP Coordination and Data Collection: An Infrastructure for COVID-19 Testing Disparities Research
RADx-UP Coordination and Data Collection: An Infrastructure for COVID-19 Testing Disparities Research Open
The COVID-19 pandemic has further exposed structural racism, inequalities, and other forms of systemic oppression that have limited opportunities for health equity and community wellbeing. Research in geographic areas with a high percenta…
View article: Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Open
File with the supplementary material & methods, supplementary tables and supplementary figure.
View article: Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Open
Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
View article: Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Open
Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
View article: Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Open
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted …
View article: Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Open
File with the supplementary material & methods, supplementary tables and supplementary figure.
View article: Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Open
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted …
View article: Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Time from prior treatment to start of treatment within this protocol
View article: Supplementary Table 2 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Table 2 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 65KB, Cancer cells were treated with DPS for 4 hr under normoxia (NO) or hypoxia (HO), and the proliferation was measured by clonogenic assay.
View article: Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Levels of eotaxin were higher in cohort A compared to cohort B. Patients with response in cohort A appeared to have high levels of eotaxin. Symbols reflect unique patients.
View article: Supplemental Table 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Table 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Per patient description of site of RT, response in irradiated volume, and baseline sum of target irradiated volume
View article: Supplemental Figure 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Figure 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Timeline of Treatment
View article: Supplementary Table 2 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Table 2 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 65KB, Cancer cells were treated with DPS for 4 hr under normoxia (NO) or hypoxia (HO), and the proliferation was measured by clonogenic assay.
View article: Supplementary Table 4 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Table 4 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 223KB, RT-qPCR validation of microarray data.
View article: Supplementary Table 3 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Table 3 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 66KB, Serum biochemistry panel.
View article: Supplementary Table 4 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Table 4 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 223KB, RT-qPCR validation of microarray data.
View article: Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Time from prior treatment to start of treatment within this protocol
View article: Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
TEAE (grade {greater than or equal to}2 events or grade 1 events occurring in {greater than or equal to}2 patients)
View article: Supplementary Figures 1 - 9 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Figures 1 - 9 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 1660KB, S1 Mouse body weight change in response to DPS treatment; S2. DPS did not induce autophagy in HI-LAPC-4 cells; S3: DPS did not induce cell cycle arrest; S4: DPS did not enhance IR-induced DNA damage; S5: DPS activity on s…
View article: Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Absolute numbers (absolute lymphocyte count * proportion) of designated cell populations at pre-treatment baseline (V1); after the completion of RT/prior to the 3rd dose of immunotherapy (week 6-9, V2); and at the timepoint of first radiog…
View article: Data from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Data from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
Purpose: Hypoxia is an important characteristic of the solid tumor microenvironment and constitutes a barrier for effective radiotherapy. Here, we studied the effects of darinaparsin (an arsenic cytotoxin) on survival and radiosensitivity …
View article: Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Additional description of correlative immunologic assays
View article: Supplementary Figure Legend from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Figure Legend from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 79KB.
View article: Supplementary Figures 1 - 9 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Figures 1 - 9 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 1660KB, S1 Mouse body weight change in response to DPS treatment; S2. DPS did not induce autophagy in HI-LAPC-4 cells; S3: DPS did not induce cell cycle arrest; S4: DPS did not enhance IR-induced DNA damage; S5: DPS activity on s…
View article: Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
TRAE (grade {greater than or equal to}2 events or grade 1 events occurring in {greater than or equal to}2 patients)
View article: Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Levels of eotaxin were higher in cohort A compared to cohort B. Patients with response in cohort A appeared to have high levels of eotaxin. Symbols reflect unique patients.
View article: Supplemental Table 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Table 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Per patient description of site of RT, response in irradiated volume, and baseline sum of target irradiated volume
View article: Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Additional description of correlative immunologic assays
View article: Supplementary Table 3 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Supplementary Table 3 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Open
PDF file, 66KB, Serum biochemistry panel.
View article: Data from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Data from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma Open
Purpose:Preclinical data suggest that radiotherapy (RT) is beneficial in combination with immune checkpoint blockade. Clinical trials have explored RT with single-agent immune checkpoint blockade, but no trials have reported RT with the co…